BeStock  
Markets › Compare › AKTS vs OMER

AKTS vs OMER

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
AKTS · Aktis Oncology$16.15 ▼ 1.52%
OMER · Omeros$13.21 ▼ 5.71%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

5988117146175Jan 9, '26Jun 17, '26Nov 20, '26
  • AKTS -27.9%
  • OMER +5.8%

Head to head

MetricAKTSOMER
Price$16.15$13.21
Change today▼ 1.52%▼ 5.71%
Market cap$901.14M$983.66M
Return, 3 months-37.8%-31.6%
Return, year to date–-23.1%
Return, 1 year–+48.9%
P/E (TTM)–8.5
P/B2.0-10.9
P/E percentile vs own 5y99th90th
Dividend yield––
Revenue growth (YoY, latest qtr)+147.3%–
Net profit growth (YoY)-92.7%+152.0%
Gross margin–97.2%
Operating margin-837.5%-189.5%
Net margin-706.8%324.9%
Return on equity-53.6%–
Analyst target vs. price+126.0%+108.2%
Analyst buy share100%100%
RSI (14)4631
30-day volatility62.9%85.2%
Max drawdown, 1 year-54.7%-49.5%
Trend readLeaning bearishStrong downtrend
Analyst consensusBuyBuy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • OMER is the largest of the group by market value.
  • OMER keeps the most profit per dollar of sales.
  • AKTS has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top